Clinical Trial Update: A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease [Phase 3]

View source ↗

Summary

Phase III trial evaluating HRS9531 for atherosclerotic cardiovascular disease is listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease

Drugs mentioned

• HRS9531

Snippet

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Conditions: Atherosclerotic Cardiovascular Disease | Phase 3 | Status: NOT_YET_RECRUITING